| 刘 雪涛 1 李 庆.类风湿性关节炎治疗药物进展[J].现代生物医学进展英文版,2015,15(6):1171-1173. |
| 类风湿性关节炎治疗药物进展 |
| Research Progress for Rheumatoid Arthritis Drugs |
| |
| DOI： |
| 中文关键词: 类风湿性关节炎 发病机制 治疗药物 |
| 英文关键词: Rheumatoid Arthritis Pathogenesis Therapeutic drugs |
| 基金项目:江苏省科技支撑计划项目 (BE2012660) |
|
| Hits: 727 |
| Download times: 4915 |
| 中文摘要: |
| 类风湿性关节炎是常见的自 身免疫性疾病，可引起关节肿痛 、畸形以及不同 程度的残疾， 影响了 患者的生活质量。 随着对发
病机制的深入研究， 出 现了 越来越多 的治疗类风湿性关节炎的药物， 依据发展的时间 及原理， 共分为 五代： 第 一代是非甾 体类抗
炎药物； 第 二代是糖皮质激素； 第三代是改变病情药（慢作用 抗风湿药）； 第 四代是以 α 肿瘤坏死因子（ TNF-α ）抑制 剂 为 主的早
期生物制剂； 第五代为直接针对 T 细胞发生作用的新型生物制 剂。 其中第 四代和第五代的生物制 剂 是近年来治疗类风湿性关节
炎的新型药物，与传统药物相比体现了 明 显的优势， 具有广泛的应用 前景。 本文对类风湿性关节炎的发病机制进行简 要阐述， 重
点对类风湿性关节炎治疗 药物的新进展进行综述。 |
| 英文摘要: |
| Rheumatoid arthritis is a common autoimmune disease, can cause joint pain, deformity and disability to varying
degrees, and affects the patient's quality of life. Along with the in-depth study of the pathogenesis, there have been a growing number of
rheumatoid arthritis drugs. Based on the time of development and principle, is divided into five generation: the first generation is
nonsteroidal antiinflammatory drugs (NSAIDs), the second generation is glucocorticoid, the third generation is disease modifying
anti-rheumatic drugs (DMARDs), also known as slow acting anti-rheumatic drugs (SAARDs), the fourth generation is early biological
agents such as TNF-琢, the fifth generation is new biological agents, which specific effect on T lymphocytes. Biological agents are novel
drugs for the treatment of rheumatoid arthritis in recent years, which reflect a clear advantage compared with traditional medicines and
have broad application prospects. This review describes the pathogenesis of rheumatoid arthritis briefly and focuses on the therapeutic
drugs. |
|
View Full Text
View/Add Comment Download reader |
| Close |
